Results 21 to 30 of about 2,123,606 (402)
Cell Death and Disease, 2022 Aggresome formation is a protective cellular response to counteract proteasome dysfunction by sequestering misfolded proteins and reducing proteotoxic stress.
Chenliang Zhang +5 more
doaj +1 more source
Cancer Cell International, 2021 Background Tumor metastasis is one of the leading reasons of the dismal prognosis of hepatocellular carcinoma (HCC). Epithelial-mesenchymal transition (EMT) is closely associated with tumor metastasis including HCC.
Gongmin Zhu +3 more
doaj +1 more source
Targeting the key cholesterol biosynthesis enzyme squalene monooxygenasefor cancer therapy
Frontiers in Oncology, 2022 Cholesterol metabolism is often dysregulated in cancer. Squalene monooxygenase (SQLE) is the second rate-limiting enzyme involved in cholesterol synthesis.
Yuheng Zou +4 more
doaj +1 more source
International Journal of Molecular Sciences, 2020 In recent years, advances in drug therapy for head and neck squamous cell carcinoma (HNSCC) have progressed rapidly. In addition to cytotoxic anti-cancer agents such as platinum-based drug (cisplatin and carboplatin) and taxane-based drugs (docetaxel and
N. Kitamura +5 more
semanticscholar +1 more source
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Molecular Cancer, 2021 Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive ...
Gongmin Zhu +4 more
doaj +1 more source
Signal Transduction and Targeted Therapy, 2023 Targeted anticancer drugs block cancer cell growth by interfering with specific signaling pathways vital to carcinogenesis and tumor growth rather than harming all rapidly dividing cells as in cytotoxic chemotherapy.
Jing-Wen Bai, Si-qi Qiu, Guo‐Jun Zhang
semanticscholar +1 more source
Frontiers in Oncology, 2022 While PARP inhibitor (PARPi) therapies have shown promising results in the treatment of high-grade serous ovarian cancer (HGSOC) harboring homologous recombination deficiencies, primary resistance to PARPi frequently occurs and even initial responders ...
Yaxun Jia +6 more
doaj +1 more source
A View of Molecular Targeted Therapies in Glioblastoma
International Journal of Research Publication and Reviews, 2023 {"references": ["Le Rhun E, Preusser M, Roth P, Reardon DA, van den Bent M, Wen P, Reifenberger G, Weller M. Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019 Nov;80:101896. doi: 10.1016/j.ctrv.2019.101896. Epub 2019 Sep 11. PMID: 31541850", "Yang, K., Wu, Z., Zhang, H. et al.
Majumdar, Esha, Chakraborty, Aria
openaire +2 more sources
Major roles of the circadian clock in cancer
Cancer Biology & Medicine, 2023 Circadian rhythms are natural rhythms that widely exist in all creatures, and regulate the processes and physiological functions of various biochemical reactions. The circadian clock is critical for cancer occurrence and progression.
Chen Huang +4 more
doaj +1 more source
Molecular imaging and targeted therapies [PDF]
Biochemical Pharmacology, 2010 Targeted therapeutic and imaging agents are becoming more prevalent, and are used to treat increasingly smaller segments of the patient population. This has lead to dramatic increases in the costs for clinical trials. Biomarkers have great potential to reduce the numbers of patients needed to test novel targeted agents by predicting or identifying non ...
Robert J. Gillies, David L. Morse
openaire +3 more sources